Nancy Uan-Tsin Lin MD

Oncology•Boston, MA

Breast Cancer

Associate Professor of Medicine, Harvard Medical School; Associate Chief, Division of Breast Oncology Center, Dana-Farber Cancer Institute

Join to View Full Profile

44 Binney St# Dana-FarBoston, MA 02115
Phone+1 617-632-3800
Fax+1 617-632-1930

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2005
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1999 - 2002
Harvard Medical SchoolClass of 1999

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 2002 - 2027
VT State Medical License 2023 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer Start of enrollment: 2007 May 14
COMPLETED
PHASE2
Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer Start of enrollment: 2007 Apr 01
Completed
Phase 1
ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases Start of enrollment: 2007 Jul 01
Terminated
Phase 2
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
TERMINATED
PHASE3
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases Start of enrollment: 2009 Nov 01
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer Start of enrollment: 2011 Aug 01
Completed
Phase 1, Phase 2
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases Start of enrollment: 2011 Oct 01
Completed
Phase 2
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
ACTIVE_NOT_RECRUITING
PHASE2
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 2
BKM120 For Triple Negative Breast Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 2
ARRY-380 + Trastuzuamab for Breast w/ Brain Mets
COMPLETED
PHASE1
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Start of enrollment: 2014 May 01
Terminated
Phase 1, Phase 2
Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer Start of enrollment: 2016 Apr 07
Completed
Phase 2
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC Start of enrollment: 2018 May 21
ACTIVE_NOT_RECRUITING
PHASE2
Clinical Information and Biospecimen Collection from Patients with Recurrent or Stage IV Breast Cancer Start of enrollment: 2019 Sep 16
SUSPENDED
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer.
Stefania Morganti, Xiangying Chu, Tarah J Ballinger, Nisha Unni, Sarah Sinclair
Clinical Breast Cancer. 2025-08-01
Clinicogenomic Characterization of Inflammatory Breast Cancer.
Nolan Priedigkeit, Beth Harrison, Robert Shue, Melissa E Hughes, Yvonne Li
Clinical Cancer Research. 2025-07-15
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metast...
Erika P Hamilton, Manish R Patel, Virginia F Borges, Jane L Meisel, Meena Okera
Breast Cancer Research. 2025-07-01

Journal Articles

Attitudes of Patients with Metastatic Cancer Towards Research Biopsies
Nancy Lin, MD, Asia‐Pacific Journal of Clinical Oncology

Press Mentions

CBD Trial Shows Promise for Cancer Anxiety ReliefDecember 17th, 2024
Managing Central Nervous System Metastasis in Patients with HER2-Positive Breast CancerOctober 22nd, 2024
T-dXd Demonstrated Intracranial Activity in HER2+ Breast CancerOctober 5th, 2024
Join now to see all

Grant Support

Dana-Farber/Harvard Cancer Center SPORE in Breast CancerDANA-FARBER CANCER INST2013–2025

Professional Memberships

American Society of Clinical Oncology - ASCO
Member